Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03992625 · ClinicalTrials.gov registry record
Clinical Outcomes for Deep Brain Stimulation
A clinical trial of Parkinson Disease and Essential Tremor, sponsored by Washington University School of Medicine.
- Recruiting
- Registry status
- 1,000
- Enrollment target
- 1
- Study location
NCT03992625: Recruiting study of Parkinson Disease and Essential Tremor, sponsored by Washington University School of Medicine.
NCT03992625 is a study of Parkinson Disease and Essential Tremor that is actively recruiting participants, run by Washington University School of Medicine. The registered enrollment target is 1,000 participants, below the 5,323-participant average among 297 other Parkinson Disease trials with a reported enrollment target (81% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03992625, a study of Parkinson Disease and Essential Tremor, is actively recruiting participants, sponsored by Washington University School of Medicine.
- RECRUITING
- Registry status
- 1,000 participants
- Enrollment target
- 1
- Study location
Study Summary
The object of this study is to longitudinally collect clinical outcomes of patients receiving deep brain stimulation for movement disorders with the objective of making retrospective comparisons and tracking of risks, benefits, and complications.
Primary Outcome
United Parkinson's Disease Rating Scale (global assessment of motor, non-motor, and quality of life associated with symptoms of Parkinson disease). Total scores range from 0-199. Particular emphasis is paid to subsection 3 (motor), where scores range from 0-56.
Conditions Studied
Interventions
- DEVICE Deep Brain Stimulation
Study Locations (1)
Missouri
- Washington University in St Louis - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,000 participants |
| Start Date | 2011-01-03 |
| Est. Completion | 2030-01-01 |
What NCT03992625 shows while recruiting
NCT03992625 is an observational study that tracks outcomes without assigning an intervention. Its 1,000 participants enrollment target places it among the larger protocols in the corpus, below the 5,323-participant average among 297 other Parkinson Disease trials with a reported enrollment target (81% lower).
The record links to 3 conditions, with Parkinson Disease appearing as the primary indexed condition, and to 1 intervention - of which Deep Brain Stimulation is the first listed.
NCT03992625 reports a single indexed study location in Missouri.
Frequently Asked Questions
What is clinical trial NCT03992625 about?
NCT03992625 is a clinical study titled "Clinical Outcomes for Deep Brain Stimulation". The object of this study is to longitudinally collect clinical outcomes of patients receiving deep brain stimulation for movement disorders with the objective of making retrospective comparisons and tracking of risks, benefits, and complications.
What is the current status of trial NCT03992625?
This trial is currently recruiting. The enrollment target is 1,000 participants. The study started on 2011-01-03. Estimated completion is 2030-01-01.
What conditions does trial NCT03992625 study?
This clinical trial studies the following conditions: Parkinson Disease, Essential Tremor, Dystonia.
What interventions are being tested in trial NCT03992625?
The interventions under investigation include: Deep Brain Stimulation (DEVICE).
Who is sponsoring clinical trial NCT03992625?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03992625 being conducted?
This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Parkinson Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03992625's enrollment target sits among peer trials
1,000 12th of 297 higher than 282 of 297 other Parkinson Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Parkinson Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Evaluation of Correlation Between Oculometric Measures and Clinical Assessment in Parkinson's Disease
RECRUITING · NA
-
Colonoscopic Detection of Phosphorylated Alpha-synuclein for Parkinson's Diagnosis
RECRUITING
-
University of Delaware Parkinson's Disease Registry
RECRUITING
-
Neocortical Microarchitecture of Executive Function
RECRUITING · NA
-
Modification of Threat Interpretation Bias to Reduce Anxiety in Neurodegenerative Movement Disorders (Aim 3)
RECRUITING · NA
-
Intranasal Insulin and Glutathione as an Add-On Therapy in Parkinson's Disease
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00018044 · 1,000 participants
Study of Mycobacterial Infections
- NCT01036581 · 1,000 participants · NA
Advanced Functional and Structural MRI Techniques for Neuropharmacological Imaging
- NCT01192048 · 1,000 participants
Genetics of Congenital Heart Disease
- NCT01553214 · 1,000 participants · Phase 4
Improving White Blood Cell Collection From Healthy Donors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI